N²
Novo Nordisk
Medical Affairs — Digital Detailing
🩺 Diabetology & Cardio-Metabolic Update · April 2026
Ozempic® — Semaglutide 0.5 mg & 1 mg
Once-weekly GLP-1 receptor agonist · Subcutaneous injection · Approved: DCGI India 2021
Headline Efficacy
Superior HbA1c reduction vs comparators across SUSTAIN 1–7
−1.8%
Mean HbA1c reduction with semaglutide 1 mg at 30 weeks vs −0.4% with placebo (SUSTAIN-1)
Across the SUSTAIN programme, semaglutide demonstrated consistent superiority over sitagliptin, exenatide ER, insulin glargine, and dulaglutide — making it the highest-efficacy GLP-1 RA in its class for glycaemic control.
−6.5 kg
Mean weight loss
Sema 1mg vs −1.9 kg placebo (SUSTAIN-1)
26%
MACE risk reduction
vs placebo in T2DM + CVD (SUSTAIN-6)
83%
Patients reaching HbA1c <7%
Sema 1mg at 30 weeks (SUSTAIN-1)
Mechanism of Action
Semaglutide is a GLP-1 analogue with 94% structural homology to human GLP-1. Its C18 fatty acid chain enables albumin binding, giving it a half-life of approximately 165 hours — the basis of once-weekly dosing.
Meal trigger
Food intake stimulates endogenous GLP-1 release
GLP-1R binding
Semaglutide binds GLP-1 receptor on β-cells and CNS
Glucose-dependent insulin
Insulin secretion amplified only when glucose is elevated
Dual protection
Glucagon suppressed · Gastric emptying slowed · Appetite reduced
Approved Indications in India
Primary Indication
Type 2 Diabetes Mellitus
As adjunct to diet and exercise to improve glycaemic control in adults with T2DM. Can be used as monotherapy or in combination with oral antidiabetics or basal insulin.
Cardiovascular Benefit
CV Risk Reduction in T2DM
To reduce the risk of major adverse cardiovascular events (MACE: CV death, non-fatal MI, non-fatal stroke) in adults with T2DM and established cardiovascular disease.
Dosing & Titration
| Week | Dose | Pen | Clinical note |
|---|---|---|---|
| Week 1–4 | 0.25 mg | Ozempic® 0.25/0.5 mg pen | Initiation dose — not therapeutic. Purpose: GI tolerability. |
| Week 5 onwards ↑ | 0.5 mg | Ozempic® 0.25/0.5 mg pen | Standard maintenance dose. Reassess HbA1c at 12 weeks. |
| If HbA1c target not met ↑ | 1.0 mg | Ozempic® 1 mg pen | Escalate after minimum 4 weeks on 0.5 mg. Maximum approved dose. |
⚠️ Indian patient consideration: Indian T2DM patients typically present at lower BMI (23–26 kg/m²) compared to Western populations. Despite lower body weight, visceral adiposity and insulin resistance remain significant. Semaglutide's weight-independent HbA1c lowering makes it particularly relevant for lean-T2DM phenotype common in South Asian patients.
Landmark Trial — SUSTAIN-6
SUSTAIN-6 — Cardiovascular Outcomes Trial
N Engl J Med 2016; 375:1834-18443,297 patients with T2DM and high CV risk randomised to semaglutide (0.5 or 1 mg) vs placebo, both on top of standard of care. Median follow-up: 2.1 years.
26%
MACE reduction (RRR)
39%
Non-fatal stroke reduction
26%
Non-fatal MI reduction
−1.1%
HbA1c at 104 weeks
−4.5 kg
Body weight change
−5 mmHg
Systolic BP reduction
Safety Profile
⚠️ Monitor — Common AEs
- Nausea (20%) — usually transient, resolves by Week 8
- Vomiting (9%) — more common at initiation
- Diarrhoea (9%)
- Constipation (5%)
- Decreased appetite — can be beneficial
✅ Favourable Profile
- Low hypoglycaemia risk (glucose-dependent)
- No dose adjustment for renal impairment (eGFR ≥15)
- Once-weekly dosing aids adherence
- CV protective — proven MACE reduction
- No titration needed for elderly patients
🛑 Contraindications
- Personal or family history of MTC
- Multiple Endocrine Neoplasia type 2 (MEN2)
- Type 1 diabetes / DKA
- Pregnancy and breastfeeding
- Hypersensitivity to semaglutide
- Severe gastroparesis (use with caution)
How Ozempic® Compares — GLP-1 RA Class
| Parameter | Semaglutide (Ozempic®) |
Dulaglutide (Trulicity®) |
Exenatide ER (Bydureon®) |
Liraglutide (Victoza®) |
|---|---|---|---|---|
| Dosing frequency | Once weekly | Once weekly | Once weekly | Once daily |
| HbA1c reduction | −1.5 to −1.8% | −1.1 to −1.4% | −1.3% | −1.2 to −1.6% |
| Weight reduction | −4.5 to −6.5 kg | −2.7 to −3.0 kg | −2.3 kg | −2.8 to −3.7 kg |
| CV outcomes trial | ✔ SUSTAIN-6 (positive) | ✔ REWIND (positive) | ✔ EXSCEL (neutral) | ✔ LEADER (positive) |
| MACE reduction | 26% RRR | 12% RRR | Not significant | 13% RRR |
| Injection device | Pre-filled pen (easy) | Pre-filled pen | Powder + reconstitution | Pre-filled pen |
Key Prescribing Messages for Your Practice
1
Start early, start confidently. Semaglutide can be initiated as second-line therapy after metformin, or even first-line if CV risk is high. Do not wait until HbA1c is above 9% — earlier initiation preserves β-cell function.
2
The nausea conversation is crucial. Warn patients proactively at initiation — "you may feel slightly nauseous in the first 4 weeks — this is normal and will resolve." Patients who are warned stay on therapy. Patients who are surprised, stop.
3
For your high-risk cardiac patients with T2DM — semaglutide is not just a diabetes drug. With a 26% MACE reduction proven in SUSTAIN-6, it is a cardiovascular intervention that also controls glucose. Frame it accordingly.
4
Storage reminder for patients: Unopened pens refrigerated (2–8°C). Once opened — room temperature (up to 30°C) for up to 6 weeks. This is a common patient error — address at first prescription.
📋 For your records: This Digital Detailing page has been prepared by Novo Nordisk India Medical Affairs, April 2026. Information is based on approved prescribing information and published clinical data. For full prescribing information refer to the approved Indian SmPC. This page is intended exclusively for registered medical practitioners and is not for distribution to patients or the public.